Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors

Neal E. Ready, Allan Lipton, Yali Zhu, Paul Statkevich, Emily Frank, Dolores Curtis, Ronald M. Bukowski

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To establish the maximum tolerated dose of the farnesyltransferase inhibitor lonafarnib (Sarasar, Schering-Plough Corp., Kenilworth, NJ) in combination with weekly paclitaxel in patients with solid tumors. Tolerability, pharmacokinetics, safety, and dose-limiting toxicity were characterized. Experimental Design: Patients were enrolled form January 2000 to May 2001. Lonafarnib was administered continuously orally twice daily at doses of 100, 125, and 150 mg in combination with paclitaxel at doses of 40, 60, or 80 mg/m2 i.v. over 1 h weekly in 28-day cycles in a phase I design. Plasma samples for determinations of lonafarnib and paclitaxel concentrations were collected at selected time points. Results: Twenty-seven patients were enrolled. The maximum tolerated dose (the dose level below where dose-limiting toxicity occurred and the recommended phase II dose) was lonafarnib 125 mg/m2 twice daily and paclitaxel 80 mg/m2 weekly. Dose-limiting toxicity was neutropenia with or without fever, which occurred in two of three patients treated at the lonafarnib 150 mg twice daily dose level. Diarrhea was a common side effect of lonafarnib but usually was mild to moderate in severity and could be controlled with standard medication without lonafarnib dose adjustment. Other reported adverse events included nausea, vomiting, fatigue, and taste changes. These adverse events were neither more frequent nor more severe than would be expected with paclitaxel alone. There were no apparent pharmacokinetic interactions between weekly paclitaxel and continuous twice-daily lonafarnib. Conclusions: The recommended dose of lonafarnib for phase II trials is 125 mg orally twice daily when combined with weekly paclitaxel 80 mg/m2. The dose-limiting toxicity was neutropenia.

Original languageEnglish (US)
Pages (from-to)576-583
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number2 I
DOIs
StatePublished - Jan 15 2007

Fingerprint

Farnesyltranstransferase
Paclitaxel
Neoplasms
Maximum Tolerated Dose
Neutropenia
Pharmacokinetics
Social Adjustment
lonafarnib
Nausea
Vomiting
Fatigue
Diarrhea
Research Design
Fever
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ready, Neal E. ; Lipton, Allan ; Zhu, Yali ; Statkevich, Paul ; Frank, Emily ; Curtis, Dolores ; Bukowski, Ronald M. / Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 2 I. pp. 576-583.
@article{3e7a94e5a56a4f238e7bbdbb6cde348c,
title = "Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors",
abstract = "Purpose: To establish the maximum tolerated dose of the farnesyltransferase inhibitor lonafarnib (Sarasar, Schering-Plough Corp., Kenilworth, NJ) in combination with weekly paclitaxel in patients with solid tumors. Tolerability, pharmacokinetics, safety, and dose-limiting toxicity were characterized. Experimental Design: Patients were enrolled form January 2000 to May 2001. Lonafarnib was administered continuously orally twice daily at doses of 100, 125, and 150 mg in combination with paclitaxel at doses of 40, 60, or 80 mg/m2 i.v. over 1 h weekly in 28-day cycles in a phase I design. Plasma samples for determinations of lonafarnib and paclitaxel concentrations were collected at selected time points. Results: Twenty-seven patients were enrolled. The maximum tolerated dose (the dose level below where dose-limiting toxicity occurred and the recommended phase II dose) was lonafarnib 125 mg/m2 twice daily and paclitaxel 80 mg/m2 weekly. Dose-limiting toxicity was neutropenia with or without fever, which occurred in two of three patients treated at the lonafarnib 150 mg twice daily dose level. Diarrhea was a common side effect of lonafarnib but usually was mild to moderate in severity and could be controlled with standard medication without lonafarnib dose adjustment. Other reported adverse events included nausea, vomiting, fatigue, and taste changes. These adverse events were neither more frequent nor more severe than would be expected with paclitaxel alone. There were no apparent pharmacokinetic interactions between weekly paclitaxel and continuous twice-daily lonafarnib. Conclusions: The recommended dose of lonafarnib for phase II trials is 125 mg orally twice daily when combined with weekly paclitaxel 80 mg/m2. The dose-limiting toxicity was neutropenia.",
author = "Ready, {Neal E.} and Allan Lipton and Yali Zhu and Paul Statkevich and Emily Frank and Dolores Curtis and Bukowski, {Ronald M.}",
year = "2007",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1262",
language = "English (US)",
volume = "13",
pages = "576--583",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2 I",

}

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. / Ready, Neal E.; Lipton, Allan; Zhu, Yali; Statkevich, Paul; Frank, Emily; Curtis, Dolores; Bukowski, Ronald M.

In: Clinical Cancer Research, Vol. 13, No. 2 I, 15.01.2007, p. 576-583.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors

AU - Ready, Neal E.

AU - Lipton, Allan

AU - Zhu, Yali

AU - Statkevich, Paul

AU - Frank, Emily

AU - Curtis, Dolores

AU - Bukowski, Ronald M.

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Purpose: To establish the maximum tolerated dose of the farnesyltransferase inhibitor lonafarnib (Sarasar, Schering-Plough Corp., Kenilworth, NJ) in combination with weekly paclitaxel in patients with solid tumors. Tolerability, pharmacokinetics, safety, and dose-limiting toxicity were characterized. Experimental Design: Patients were enrolled form January 2000 to May 2001. Lonafarnib was administered continuously orally twice daily at doses of 100, 125, and 150 mg in combination with paclitaxel at doses of 40, 60, or 80 mg/m2 i.v. over 1 h weekly in 28-day cycles in a phase I design. Plasma samples for determinations of lonafarnib and paclitaxel concentrations were collected at selected time points. Results: Twenty-seven patients were enrolled. The maximum tolerated dose (the dose level below where dose-limiting toxicity occurred and the recommended phase II dose) was lonafarnib 125 mg/m2 twice daily and paclitaxel 80 mg/m2 weekly. Dose-limiting toxicity was neutropenia with or without fever, which occurred in two of three patients treated at the lonafarnib 150 mg twice daily dose level. Diarrhea was a common side effect of lonafarnib but usually was mild to moderate in severity and could be controlled with standard medication without lonafarnib dose adjustment. Other reported adverse events included nausea, vomiting, fatigue, and taste changes. These adverse events were neither more frequent nor more severe than would be expected with paclitaxel alone. There were no apparent pharmacokinetic interactions between weekly paclitaxel and continuous twice-daily lonafarnib. Conclusions: The recommended dose of lonafarnib for phase II trials is 125 mg orally twice daily when combined with weekly paclitaxel 80 mg/m2. The dose-limiting toxicity was neutropenia.

AB - Purpose: To establish the maximum tolerated dose of the farnesyltransferase inhibitor lonafarnib (Sarasar, Schering-Plough Corp., Kenilworth, NJ) in combination with weekly paclitaxel in patients with solid tumors. Tolerability, pharmacokinetics, safety, and dose-limiting toxicity were characterized. Experimental Design: Patients were enrolled form January 2000 to May 2001. Lonafarnib was administered continuously orally twice daily at doses of 100, 125, and 150 mg in combination with paclitaxel at doses of 40, 60, or 80 mg/m2 i.v. over 1 h weekly in 28-day cycles in a phase I design. Plasma samples for determinations of lonafarnib and paclitaxel concentrations were collected at selected time points. Results: Twenty-seven patients were enrolled. The maximum tolerated dose (the dose level below where dose-limiting toxicity occurred and the recommended phase II dose) was lonafarnib 125 mg/m2 twice daily and paclitaxel 80 mg/m2 weekly. Dose-limiting toxicity was neutropenia with or without fever, which occurred in two of three patients treated at the lonafarnib 150 mg twice daily dose level. Diarrhea was a common side effect of lonafarnib but usually was mild to moderate in severity and could be controlled with standard medication without lonafarnib dose adjustment. Other reported adverse events included nausea, vomiting, fatigue, and taste changes. These adverse events were neither more frequent nor more severe than would be expected with paclitaxel alone. There were no apparent pharmacokinetic interactions between weekly paclitaxel and continuous twice-daily lonafarnib. Conclusions: The recommended dose of lonafarnib for phase II trials is 125 mg orally twice daily when combined with weekly paclitaxel 80 mg/m2. The dose-limiting toxicity was neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=33846857560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846857560&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1262

DO - 10.1158/1078-0432.CCR-06-1262

M3 - Article

VL - 13

SP - 576

EP - 583

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2 I

ER -